Hennion & Walsh Asset Management Inc. Trims Stock Holdings in Grifols, S.A. (NASDAQ:GRFS)

Hennion & Walsh Asset Management Inc. lowered its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 6.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 244,151 shares of the biotechnology company’s stock after selling 16,093 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Grifols were worth $2,168,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. B. Riley Wealth Advisors Inc. purchased a new stake in Grifols during the 2nd quarter worth about $359,000. Sei Investments Co. lifted its holdings in shares of Grifols by 5.3% in the first quarter. Sei Investments Co. now owns 2,109,416 shares of the biotechnology company’s stock worth $14,091,000 after buying an additional 107,000 shares in the last quarter. Team Hewins LLC boosted its position in shares of Grifols by 11.8% in the first quarter. Team Hewins LLC now owns 40,818 shares of the biotechnology company’s stock valued at $273,000 after acquiring an additional 4,324 shares during the period. Hantz Financial Services Inc. purchased a new position in Grifols during the second quarter valued at approximately $1,235,000. Finally, Natixis Advisors LLC increased its holdings in Grifols by 116.0% during the 2nd quarter. Natixis Advisors LLC now owns 154,053 shares of the biotechnology company’s stock worth $971,000 after acquiring an additional 82,723 shares during the period.

Grifols Stock Performance

NASDAQ GRFS opened at $8.73 on Friday. The company’s 50 day simple moving average is $8.75 and its two-hundred day simple moving average is $7.73. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.68 and a quick ratio of 0.80. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $12.15. The stock has a market capitalization of $6.00 billion, a PE ratio of 8.56 and a beta of 0.50.

Grifols (NASDAQ:GRFS) last issued its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). The company had revenue of $1.96 billion during the quarter. Analysts predict that Grifols, S.A. will post 0.79 earnings per share for the current fiscal year.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.